



A Meeting of the **Borders Area Drugs and Therapeutics Committee** was held at 12.30 p.m. on Wednesday, 9th May 2012 in the Committee Room, Education Centre.

MINUTE

Situation - A concise statement of the problem (What is going on now in relation to agenda item)

Background - Pertinent and brief information related to the situation (What has happened)

Assessment - Analysis and considerations of options (What your analysis of background information is Current Position/Outcome)

Recommendation - Request or recommend action (What you want to be done)

1. Present: John Hammond (Chair) (JH), Ros Anderson (RA), Catherine Scott (CS), Adrian Mackenzie (AMack), Paul Marynicz (PM), Mark Clark (MC), Gavin Gorman (GG), Liz Leitch (LL) Joanna Smith (JS), Cliff Sharp (CS) Peter Symms (PS), Edward James (EJ), Tom Cripps (TC), Ross Cameron (RC), Olive Herlihy (OH)

Invited to attend: Sarah McAleer – Clinical Pharmacist & Joanna Cooper – Prescribing Support Team Dietician

Apologies: Declan Hegarty (DH), Alison Wilson (AW)

Date of Meeting	Item No.	Situation	Background	Assessment	Recommendation	Person Responsible	Timescale
	2.	Declaration of Interest: None					
	3.	Draft minute from ADTC of 14.03.12	Minute from previous meeting	Read and noted for accuracy.	Approved as true record	Chair	Complete
	4.	Matters Arising From Previous Minute:					
		Restricted number of BNF's available.	Wards using increasingly out of date copies.	Consultants to hand back their up to date copies as could be used on the wards.	Agreed to gather in Edition 62 for recycling. JH to raise at next Public Board meeting. AW to put in risk register.	SH JH AW	11.07.12 11.07.12 11.07.12
		Quickmist - Applicant to	Smoking Cessation team had	No evidence to	Agreed not to add to	Chair to write	Complete

		feedback after 20 patients	made application to prescribe this product to patients.	support that it is better than any other medication available.	the formulary.	to applicant	
		Yellow Card Scheme	Annual Report – April 2010 – March 2011	Report not signed of as yet.	Contact and ask for final report. Reminder to go in the next prescribing bulletin. To be discussed at a Grand Round.	GG RA EJ	Complete
	5.	Draft Minute of BFC meeting of 18 th April 2012	For information only	ADTC to ratify NMA's from BFC meeting	To approve or not to approve BFC decision	ADTC Group Members	Complete
	6.	Applications for Approval from BFC of 18th April 2012					
		Paliperidone	New medicines application.	Prolonged release suspension for injection.	Ratified by group for 3 patients only.	Bring back to next BFC meeting	BFC 13.06.12
		Nortriptyline	For neuropathic pain	Decision from BFC requires to be ratified by ADTC.	Approved as CAT 'A'	As above.	As above
		Pregabalin	For use in patients who have not achieved pain relief or tolerated 1 st & 2 nd line treatments for peripheral neuropathic pain	As above	Approved for up to 120 patients per year CAT 'A'	As above	As above
		Lidocaine	Localised neuropathic pain.	Approved for up to 60 patients per year.	Request copy of previous audit done by pain team.	RA	11.07.12
		Romiplostim	For use in adults with chronic immune thrombocytopenic purpura splenectomised patients who are refractory to other treatments.	Noted as being a very expensive drug.	Noted and ratified.	As above.	Complete
		Etanercept	For use in systemic juvenile	Approved for	As above	As above	Complete

			idiopathic arthritis.	named patient only.			
		Nutricia preOp	For use in the enhanced recovery after surgery programme.	No other product available in current use.	As above	As above	Complete
		Dexamphetamine complex	Use in ADHD patient.	For one patient only.	As above	As above	Complete
		Ustekinumab	For use in patients who have failed to respond to or who have a contraindication to or intolerant to other systemic therapies including ciclosporin, methotrexate and psoralen and UVA treatment.	Reminder put into next prescribing bulletin re GP's including secondary care drugs in EMIS summaries	As above	As above	Complete
		Orlistat	Weight loss in adults who are overweight (BMI>28kg/m ²)	BFC of 18.04.12 – Approved for patients with BMI >35 for GP use with input from dietetic service.	Contact Perry Burgess and Joeleen McKean asking for guidance for GP's before goes into formulary.	LL	11.07.12
		PleureX	Palliative care team wish to use proposed indication malignant recurrent ascites.	Jenni Smith to discuss with Shona Hall in procurement	JS off sick bring back to next BFC meeting.	JS	13.06.12
		Colecalciferol Fultium D3	To be used as an adjunct to specific therapy for osteoporosis in patients with Vit D deficiency at risk of Vit D insufficiency.	Supply problems of unlicensed drug, now replaced with licensed preparation.	Noted and ratified	Chair to write to applicant	Complete
		Capsaicin	Treatment of peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain.	Awaiting guidance but approved for one patient.	To be carried forward to next meeting.	SH	11.07.12
		Clobetasol Propionate	Topical treatment of moderate	Replaces and	Noted and ratified.	Chair to write	Complete

		Shampoo	scalp psoriasis in adults.	augments other products		to applicant.		
		Flourouracil 0.5% Salicylic Acid 10% Cutaneous Sol	Topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (grade 1/11) in Immunocompetent adult patients.	Quick response as early as 6 weeks.	Noted and ratified.	As above	Complete	
		Rivaroxaban	Treatment of deep vein thrombosis & prevention of recurrent DVT & pulmonary embolism following an acute DVT in adults.	Oral drug no need for monitoring INR. LL reported one is in the process of setting up a group to discuss implementation in NHS Borders.	Noted and ratified	As above	Complete	
	7.	New Medicine Applications:						
		Denosumab - Osteoporotic fractures needs bone protecting medication. Cost of 1 month's treatment £30 for use in 2 male patients.	Impaired renal function bisphosphonates should be avoided. Denosumab known to be safe in renal failure patients.	Off label use, no supporting evidence and unlicensed for use in males.	Will reconsider when supporting evidence received. LL will contact to provide for next BFC meeting.	LL	BFC 13.06.12	
		Budesonide - Eosinophilic oesophagitis. Dose to be identified but 1mg/day would equate to £45.45.	Currently difficult to deliver steroid to the oesophageal mucosa.	Off label use for 1 patient.	Approved for specialist use only CAT 'B'	Chair to write to applicant.	Complete	
		Apixaban - New oral anticoagulant for DVT & PE Thrombo prophylaxis.	New oral anticoagulant similar to Rivaroxaban.	Unknown number of patients in first year.	Not approved. Group to look again in a year's time. (Other drug already being introduced into practice).	Chair to write to applicant.	Complete	

		Buprenorphine & Naloxone Tabs.	To replace Buprenorphine in the formulary. (Reduces risk of injection of buprenorphine).	Using combination is more cost effective than using Buprenorphine alone.	LL to liaise with Mike Kehoe & Adrian Mackenzie	LL	11.07.12
		Chlordiazepoxide PGD Lofexidine draft PGD Alcohol Chlordiazepoxide detox guideline Opiate detox guidelines with Lofexidine	Some GP's are refusing to prescribe these drugs for home detox due to lack of control of how many tablets patients are taking. Consultant for Addiction Service is prescribing the drugs in the interim.	Nurse involved in patient care can follow pgd, make changes and implement.	GP sub have asked the Addiction Service to produce a pgd to allow supply. Invite nurse from addiction service to next meeting.	Chair/ Mike Kehoe, Addiction Service	11.07.12
	8.	Borders Joint Formulary Update. Section 13 – 13.1 Management of skin conditions	Revised section of formulary	To be first choice for new treatments in formulary.	Update formulary.	LL	Bring back NMA's for new products to BFC.
	9.	Additional Item Regarding Shortage of BNF's on Wards -	Patient safety is compromised by shortage of available BNF's on wards & OPD and issued to practitioners.	Raise awareness of this shortage to appropriate personnel. Increase number of BNF's available	Discussed under item 4.	See above.	See above.
	10.	Shortages with Xenical (orlistat) likely to last several months	OTC preparations can be prescribed on a GP10 when product unavailable due to shortages but issues around differing licence agreements for the product.	Patients can buy this product over the counter if they wish. 91 patients on this drug how much combined weight have they lost?	Ask Dr Declan Hegarty to bring back to next meeting.	DH	11.07.12

	11.	Neuropathic Guidance	Previously presented to ADTC but changes have been made as requested and also to add extra clarity as a result of drug applications to BFC on 18.04.12	Changes made to original application as requested.	Bring back to next ADTC meeting.	SH to go on next agenda	11.07.12
		For Information and Noting Only:					
	12.	Pyrimethamine Sulfadiazine	Urgent script requested from ophthalmology for pyrimethamine and sulphadiazine for an eye infection.	Medication has been ordered.	Noted by ADTC members	Dr R Murray	Complete
	13.	Audit and Improvement Project on MRSA eradication	Previous audit has shown poor prescribing of MRSA eradication within BGH. Draft protocol was drawn up in 2010 to allow ICN's to prompt ward Dr prescribing by use of pre-printed stickers for the drug Kardex. Protocol has not been piloted yet. Ward 10 junior Dr intends using this sticker based approach as a way of improving the prescribing of MRSA eradication.	Ward 10 junior Dr will audit MRSA prescribing on ward 10. Pre printed kardex stickers, affixed by nurses, which must be signed by a Dr before administration can occur, will be piloted as an improvement method.	After initial audit this will be continued throughout the wards at the BGH.	Anne Duguid/Dr E James	Ongoing
	14.	SOP IV Therapy	Revised March 2012 V1	Adjustment made and back for noting.	ADTC group	Christine Irving/GG	Complete
	15.	Patient Access Scheme Implementation Pack	Icatibant acetate Guidance Notes	NHS Borders currently using a drug called Berinert.	We need to review what is currently being used within NHS Borders	AW	11.07.12
	16.	A.O.C.B 2 PGD's for mupirocin 2 Protocols each for chlorhexidine topical solution & mouthwash	For the treatment of renal dialysis patients.	Solution & mouthwash are not prescription only medicines so do not require	Approved	AD/EJ	Complete

				PGD but is still advisable to have all the information that would have been in a PGD in some useful format.			
	17.	Next Meeting: Wednesday, 11 th July 2012 at 12.30 p.m. in the Estates Meeting Room, BGH					